Pharmaceuticals News and Research

RSS

NeuroDerm launches initial public offering of 4,500,000 shares

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC).

3 Nov 2014

Cogent OA teams up with Medpharm Publications to co-publish society-affiliated journals

Cogent OA is delighted to announce a partnership with Medpharm Publications of South Africa to co-publish several of its society-affiliated journals, providing leading online functionality and marketing services to further increase visibility and global reach.

3 Nov 2014

Epicure project: an interview with Frédéric Cren

Epicure is a project led by Inventiva and Institut Curie that aims to deliver pre-clinical candidates on two novel epigenetic targets that have been selected due to their potential to activate immune responses against cancer cells. In addition one of these two targets has potential in respiratory indications such as asthma or COPD.

3 Nov 2014

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

In support of a bold quest to rid the world entirely of malaria, the Bill & Melinda Gates Foundation today announced an award of US$156 million to PATH to support the PATH Malaria Vaccine Initiative (MVI) in building new vaccines that will interrupt the cycle of malaria parasite transmission and help realize the "accelerating to zero" agenda. Such vaccines would ensure that parasite reintroduction is prevented by providing what could be called an "immunological bed net."

3 Nov 2014

Zebra Imaging enters into strategic partnership with Zygote Media Group

Zebra Imaging, Inc., the world's foremost provider of 3D holographic visualization technologies announced today a strategic partnership with the Zygote Media Group Inc., the industry leader in high-end 3D anatomy and biomedical models for animation and visual effects, to serve the medical and medical education markets.

31 Oct 2014

New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

Oligonucleotide-based therapeutics present unique challenges when it comes to testing their potential to cause reproductive and developmental harm. New consensus guidelines for toxicity testing that take into consideration the combined chemical and biological characteristics of these novel biopharmaceuticals are presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

31 Oct 2014

Veloxis receives tentative FDA approval for Envarsus XR

Veloxis Pharmaceuticals A/S announced today that the U.S. Food and Drug Administration has informed Veloxis of the tentative approval of Envarsus XR. FDA stated that the final approval of Envarsus XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL.

31 Oct 2014

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals, Inc. today announced the publication of results from TARGET, a pivotal phase III study evaluating the efﬁcacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available).

30 Oct 2014

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014.

30 Oct 2014

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that its lead product ATIR has been granted Orphan Drug Designation (ODD) by the European Medicines Agency for the treatment of acute myeloid leukemia (AML).

30 Oct 2014

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride Tablets USP, 23 mg, the generic equivalent to Eisai Inc.'s Aricept 23mg.

30 Oct 2014

New international consortium to advance GPCR research for drug development

The generation of high-resolution pictures of hundreds of medically important proteins known as G-protein coupled receptors (GPCRs) will be the goal of an ambitious new international partnership. Called the GPCR Consortium, this non-profit initiative brings together major pharmaceutical companies and leading research institutes from three continents to advance GPCR research for drug development.

29 Oct 2014

UW-Madison receives $8.3 million NIH grant to create new urological research center

The University of Wisconsin-Madison has been awarded an $8.3 million grant from the National Institutes of Health to create a research center focused on urological health.

29 Oct 2014

GE Healthcare launches startup campus Health Innovation Village to help entrepreneurs speed up health tech solutions

Today GE Healthcare officially opens Health Innovation Village, its first health tech startup campus, at its Finnish headquarters with the Minister of Economic Affairs in Finland, Jan Vapaavuori and the Mayor of Helsinki, Jussi Pajunen.

29 Oct 2014

Generic aromatase inhibitors increase breast cancer treatment adherence by 50%

Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor-positive tumors, about one-half of patients fail to take their medications as directed. A new study by Columbia University Medical Center researchers has found that the introduction of generic aromatase inhibitors (the most common type of hormone therapy), which are considerably less expensive than their brand name counterparts, increased treatment adherence by 50 percent.

28 Oct 2014

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'.

28 Oct 2014

Encouraging Life science Investment in Northern England

An interview with Dr. Geoff Davison, discussing the major barriers to biomedical investment in the North of England.

27 Oct 2014

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand.

27 Oct 2014

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Clementia Pharmaceuticals, Inc. announced today the initiation of a Phase 2 extension study of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), a rare, severely disabling genetic disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and new abnormal bone formation.

27 Oct 2014

Vanda reports total revenues of $14.8 million for third quarter 2014

Vanda Pharmaceuticals Inc., today announced financial and operational results for the third quarter ended September 30, 2014.

27 Oct 2014

Pharmaceuticals News and Research

NeuroDerm launches initial public offering of 4,500,000 shares

Cogent OA teams up with Medpharm Publications to co-publish society-affiliated journals

Epicure project: an interview with Frédéric Cren

Gates Foundation awards US$156 million to support PATH Malaria Vaccine Initiative

Zebra Imaging enters into strategic partnership with Zygote Media Group

New consensus guidelines for toxicity testing of oligonucleotide-based therapeutics

Veloxis receives tentative FDA approval for Envarsus XR

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Kiadis Pharma's ATIR product receives EMA's ODD for treatment of acute myeloid leukemia

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

New international consortium to advance GPCR research for drug development

UW-Madison receives $8.3 million NIH grant to create new urological research center

GE Healthcare launches startup campus Health Innovation Village to help entrepreneurs speed up health tech solutions

Generic aromatase inhibitors increase breast cancer treatment adherence by 50%

Imaxio awarded ANR funding to improve efficacy of vaccines for seasonal influenza

Encouraging Life science Investment in Northern England

PlasmaTech Biopharmaceuticals inks agreement to commercialize MuGard in Australia, New Zealand

Clementia initiates Phase 2 extension study of palovarotene in FOP patients

Vanda reports total revenues of $14.8 million for third quarter 2014

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence